Spine Market Size and Share
Market Definition
Hardware to treat degenerative disc disease, herniated discs, scoliosis and vertebral fractures.
April 2026
Mike Evers, Senior Market Analyst
Welcome to our spine market overview, a companion to the spine chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®. The competitive landscape has shifted dramatically in recent quarters, and we anticipate more changes.
The Market at a Glance
Spine is a large and mature market that is undergoing a period of significant disruption in its competitive landscape. Digital ecosystems have become a strategic battleground for some of the largest companies while others are leaving the spine market outright.
Market Forecast
Spine experienced low 3% growth in 2025, a rate we expect the market to continue at in the coming years. We estimate that the market will surpass $12 billion in 2028 and $12.5 billion in 2029.
Exhibit 1: Worldwide Spine Sales by Year ($million)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 80 public and private companies by segment from 2016 through 2025.
Here are some of the spine market dynamics we considered in our forecasts:
Accelerating Demand for Care. Spine surgical volumes will increase as the global population grows and ages. The number of people aged 60 or older will double between 2020 and 2050, from one billion to 2.1 billion. Back pain affects one in 10 people globally and is the primary cause of disability in the United States, costing the federal government $560 billion annually due to treatment expenses and productivity loss. Spine companies seek ways to improve the efficiency and accuracy of treatment without ballooning the costs of care.
Smaller Incisions Signal Improved Outcomes. Minimally invasive procedures represent the future of spine surgery. They produce better outcomes, reduce patient morbidity and are better suited to alternative sites of care. Minimally invasive procedures account for an estimated 20% to 30% of total spine cases in the United States. Companies outside of spine, like Arthrex, are increasingly applying their technologies to spine surgery. As more surgeons adopt minimally invasive techniques, we expect the rate of product and outcome improvements to accelerate.
Novel Technologies Gaining Adoption. The success of companies like SI-BONE, Centinel Spine and Carlsmed underscore novel spine subsegments that could drive future growth. SI-BONE has grown at least 20% every year since its 2018 IPO and surpassed $200 million in revenue during 2025. Centinel Spine marked the milestone of more than 300,000 prodisc devices implanted worldwide and achieved FDA approval for two-level use of the prodisc C Vivo and prodisc C SK cervical TDR devices. Carlsmed continues to prove its beneficial impact on patient outcomes and the economics of care as the only spine company to offer personalized implant designs. The company has reduced lead times to just six days and showed a 74% reduction in reoperation rates among adult spinal deformity patients who received aprevo lumbar implants versus those who received stock implants.
Other Segment Reports
Sales by Region
The U.S. spine market remains highly competitive given the number of companies vying for share. At the top of the market, a robust enabling technology ecosystem is essentially required to keep pace with companies like Medtronic and Globus Medical that are using these systems to lock in strategic accounts and wall off challengers.
Outside the United States, the top spine players are focused on narrow but deep investments into geographies that can support sales of newer, flagship implants and technologies. Western Europe, Australia, Japan and Brazil are some of the most cited market opportunities for spine players in 2026 and beyond. As always, quarterly results from international markets can be choppy but these regions hold long-term promise.
Exhibit 2: Spine Sales by Region ($million)
| Region | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $7,896.8 | $7,637.1 | $259.7 | 3.4% |
| OUS | $3,241.2 | $3,149.8 | $91.4 | 2.9% |
| EMEA | $1,854.5 | $1,790.6 | $63.9 | 3.6% |
| APAC | $1,077.0 | $1,057.1 | $19.9 | 1.9% |
| ROW | $309.6 | $302.0 | $7.6 | 2.5% |
| Total | $11,138.0 | $10,786.9 | $351.1 | 3.3% |
Exhibit 3: Spine Market Share by Region ($millions)
Top Companies
Medtronic and Globus Medical dominate the market, accounting for nearly 43% of global spine sales. All other players have 8% market share or less. DePuy Synthes and ATEC occupy the next tier down, followed by a significant drop off to mid-tier companies like VB Spine, Highridge Medical and Orthofix.
Exhibit 4: Top 10 Spine Players and All Others ($millions)
| Company | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| Medtronic | $2,547.0 | $2,401.2 | $145.8 | 6.1% |
| Globus Medical | $2,247.7 | $2,126.7 | $121.0 | 5.7% |
| J&J MedTech | $883.5 | $934.1 | ($50.6) | (5.4%) |
| ATEC | $622.2 | $492.9 | $129.2 | 26.2% |
| VB Spine | $369.8 | $0.0 | $0.0 | 0% |
| Highridge Medical | $353.5 | $343.5 | $10.0 | 2.9% |
| Orthofix | $298.8 | $285.9 | $12.9 | 4.5% |
| SI-BONE | $200.9 | $167.2 | $33.7 | 20.2% |
| Stryker | $185.0 | $707.0 | ($522.0) | (73.8%) |
| Aesculap | $133.2 | $129.2 | $4.0 | 3.1% |
| All Others | $3,296.4 | $3,199.0 | $97.4 | 3% |
| Total | $11,138.0 | $10,786.9 | $351.1 | 3.3% |
Exhibit 5: Spine Market Share by Company ($million)
The battle between Medtronic and Globus Medical has brought enabling technology to the fore of spine’s competitive landscape. It seems like Medtronic has the upper hand in this battle, at least for now. Globus Medical saw elongated selling cycles for its enabling technology during most of 2025. Meanwhile, Medtronic announced the FDA clearance of its next-generation Stealth AXiS system.
The need for digital solutions has driven smaller companies out of contention at strategic accounts and caused larger players to exit the space entirely.
DePuy Synthes’ spine business has been under extreme competitive pressure for several years and the company’s impending separation from J&J MedTech is unlikely to offer any easy answers. DePuy Synthes will need to make significant investments in spine to become competitive again or look to divest its spinal assets.
DePuy Synthes has been one of the major share donors that has helped ATEC’s incredible growth. DePuy Synthes’ spine business has been beset by competitive pressures for years and will require significant investment to go back on offense. ATEC’s sole focus on spine and its procedural approach has resonated with surgeons. To be fair, ATEC has taken market share from all of the market’s major players given its consistent, market-leading growth rate.
VB Spine and Highridge Medical emerged out of large strategics that called it quits on the spine market and both companies have focused on acquiring technology through development or partnership deals to fully compete at the highest echelon of the market.
More specialized players experienced strong year-over-year growth. SI-BONE , Centinel Spine (+34.4%) and Carlsmed (+86%) have parlayed their unique product offerings to substantial growth and could become more disruptive forces as they continue to gain adoption.
Important Developments in the Spine Market
Market Share Moats. In 2023, we talked about how the closed model of robotics and enabling technology was a key initiative for the largest companies to dominate strategically important accounts and protect implant market share. We wondered if the inefficiencies of that model might drive hospital administrators to the open model of robotics. While the open model has taken some steps since then, the closed model appears stronger than ever. Medtronic has benefited from health systems upgrading not just single pieces of capital but adding the full AiBLE ecosystem, which creates a strong competitive moat around the company’s spine business. Still, we expect smaller spine-focused companies to invest in enabling technology to maintain their competitiveness.
Acquisition and Investment Focus. Spine remains the most active category for orthopedic M&A and funding. However, that focus has been shifting to other segments over the last five years. From 2016 to 2020, 30% of all M&A was spine related. From 2021 to 2025, that percentage dropped to 24%. Spine saw a similar drop in funding for those years, going from 30% of all investment announcements to 25%. Looking at dollars invested, the drop is even more precipitous, declining 17%. In both M&A and investments, much of that activity has shifted to digital solutions and orthobiologics.
A Mostly Inpatient Industry. While orthopedic procedures are moving to alternative sites of care, spine surgery is mostly performed at inpatient hospital settings because of procedural complexity, operating requirements and reimbursement dynamics. Inpatient reimbursement has been mostly flat, while outpatient rates have climbed steadily. The remaining gap provides limited financial incentive to move cases to outpatient settings. Some spine surgeries have made meaningful inroads to the ASC, however, including lumbar fusion, simple cervical cases and decompressions.
Motion Preservation Momentum. Non-fusion technologies continue to advance and are expected to gain greater adoption as more implants reach the market and surgeons better qualify the patients best served by these options. Two of three orthopedic Premarket Approvals in 2025 were for spine implants: Companion Spine’s DIAM Spinal Stabilization System and Centinel Spine’s prodiscC Vivo and prodisc C SK Cervical received two-level vertebrae indication. Empirical Spine’s LimiFlex Dynamic Sagittal Tether received a PMA at the beginning of 2026. We expect this portion of the market to grow, as reimbursement improves and surgeons favor minimally invasive procedures for spine candidates.
SI Joint Fusion Remains Hot. The sacroiliac (SI) joint fusion remains one of the faster-growing subsegments of spine due to a greater focus on the segment by surgeons and companies. SI-BONE, a leader in the space, says SI joint dysfunction has a large addressable market with strong fundamentals. While the market is expected to grow due to more minimally invasive options and greater awareness from surgeons, including pain management physicians, we wonder when the segment will reach oversaturation with available products. Established spine companies have added SI joint implants to their portfolios in recent years and three of the seven companies that received their first FDA 510(k) in 2025 introduced an implant in this category.
Saving the Disc. Biologic responses to halt degenerative disc disease is predicted to be the future of spine care. Over two dozen companies are actively developing products for intervertebral disc repair and restoration, establishing a strong pipeline of potential options in the future. These approaches could help bridge the gap between conservative treatment, spinal fusions and disc replacements.
Further Reading
Thanks for visiting! Need more insight on the spine market? Questions and comments are always welcome. You can reach me by email. Until then, I’ve selected a few posts that give insight into our thinking on the spine market.
Our overview of the spine implant market includes up-to-date information on forecasted growth, the top companies and industry-driving trends.
Market Definition
Hardware to treat degenerative disc disease, herniated discs, scoliosis and vertebral fractures.
April 2026
Mike Evers, Senior Market Analyst
Welcome to our spine market overview, a companion to the spine chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®. The competitive landscape has shifted dramatically in recent quarters, and we anticipate more changes.
The Market at a Glance
Spine is a large and mature market that is undergoing a period of significant disruption in its competitive landscape. Digital ecosystems have become a strategic battleground for some of the largest companies while others are leaving the spine market outright.
Market Forecast
Spine experienced low 3% growth in 2025, a rate we expect the market to continue at in the coming years. We estimate that the market will surpass $12 billion in 2028 and $12.5 billion in 2029.
Exhibit 1: Worldwide Spine Sales by Year ($million)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 80 public and private companies by segment from 2016 through 2025.
Here are some of the spine market dynamics we considered in our forecasts:
Accelerating Demand for Care. Spine surgical volumes will increase as the global population grows and ages. The number of people aged 60 or older will double between 2020 and 2050, from one billion to 2.1 billion. Back pain affects one in 10 people globally and is the primary cause of disability in the United States, costing the federal government $560 billion annually due to treatment expenses and productivity loss. Spine companies seek ways to improve the efficiency and accuracy of treatment without ballooning the costs of care.
Smaller Incisions Signal Improved Outcomes. Minimally invasive procedures represent the future of spine surgery. They produce better outcomes, reduce patient morbidity and are better suited to alternative sites of care. Minimally invasive procedures account for an estimated 20% to 30% of total spine cases in the United States. Companies outside of spine, like Arthrex, are increasingly applying their technologies to spine surgery. As more surgeons adopt minimally invasive techniques, we expect the rate of product and outcome improvements to accelerate.
Novel Technologies Gaining Adoption. The success of companies like SI-BONE, Centinel Spine and Carlsmed underscore novel spine subsegments that could drive future growth. SI-BONE has grown at least 20% every year since its 2018 IPO and surpassed $200 million in revenue during 2025. Centinel Spine marked the milestone of more than 300,000 prodisc devices implanted worldwide and achieved FDA approval for two-level use of the prodisc C Vivo and prodisc C SK cervical TDR devices. Carlsmed continues to prove its beneficial impact on patient outcomes and the economics of care as the only spine company to offer personalized implant designs. The company has reduced lead times to just six days and showed a 74% reduction in reoperation rates among adult spinal deformity patients who received aprevo lumbar implants versus those who received stock implants.
Other Segment Reports
Sales by Region
The U.S. spine market remains highly competitive given the number of companies vying for share. At the top of the market, a robust enabling technology ecosystem is essentially required to keep pace with companies like Medtronic and Globus Medical that are using these systems to lock in strategic accounts and wall off challengers.
Outside the United States, the top spine players are focused on narrow but deep investments into geographies that can support sales of newer, flagship implants and technologies. Western Europe, Australia, Japan and Brazil are some of the most cited market opportunities for spine players in 2026 and beyond. As always, quarterly results from international markets can be choppy but these regions hold long-term promise.
Exhibit 2: Spine Sales by Region ($million)
| Region | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $7,896.8 | $7,637.1 | $259.7 | 3.4% |
| OUS | $3,241.2 | $3,149.8 | $91.4 | 2.9% |
| EMEA | $1,854.5 | $1,790.6 | $63.9 | 3.6% |
| APAC | $1,077.0 | $1,057.1 | $19.9 | 1.9% |
| ROW | $309.6 | $302.0 | $7.6 | 2.5% |
| Total | $11,138.0 | $10,786.9 | $351.1 | 3.3% |
Exhibit 3: Spine Market Share by Region ($millions)
Top Companies
Medtronic and Globus Medical dominate the market, accounting for nearly 43% of global spine sales. All other players have 8% market share or less. DePuy Synthes and ATEC occupy the next tier down, followed by a significant drop off to mid-tier companies like VB Spine, Highridge Medical and Orthofix.
Exhibit 4: Top 10 Spine Players and All Others ($millions)
| Company | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| Medtronic | $2,547.0 | $2,401.2 | $145.8 | 6.1% |
| Globus Medical | $2,247.7 | $2,126.7 | $121.0 | 5.7% |
| J&J MedTech | $883.5 | $934.1 | ($50.6) | (5.4%) |
| ATEC | $622.2 | $492.9 | $129.2 | 26.2% |
| VB Spine | $369.8 | $0.0 | $0.0 | 0% |
| Highridge Medical | $353.5 | $343.5 | $10.0 | 2.9% |
| Orthofix | $298.8 | $285.9 | $12.9 | 4.5% |
| SI-BONE | $200.9 | $167.2 | $33.7 | 20.2% |
| Stryker | $185.0 | $707.0 | ($522.0) | (73.8%) |
| Aesculap | $133.2 | $129.2 | $4.0 | 3.1% |
| All Others | $3,296.4 | $3,199.0 | $97.4 | 3% |
| Total | $11,138.0 | $10,786.9 | $351.1 | 3.3% |
Exhibit 5: Spine Market Share by Company ($million)
The battle between Medtronic and Globus Medical has brought enabling technology to the fore of spine’s competitive landscape. It seems like Medtronic has the upper hand in this battle, at least for now. Globus Medical saw elongated selling cycles for its enabling technology during most of 2025. Meanwhile, Medtronic announced the FDA clearance of its next-generation Stealth AXiS system.
The need for digital solutions has driven smaller companies out of contention at strategic accounts and caused larger players to exit the space entirely.
DePuy Synthes’ spine business has been under extreme competitive pressure for several years and the company’s impending separation from J&J MedTech is unlikely to offer any easy answers. DePuy Synthes will need to make significant investments in spine to become competitive again or look to divest its spinal assets.
DePuy Synthes has been one of the major share donors that has helped ATEC’s incredible growth. DePuy Synthes’ spine business has been beset by competitive pressures for years and will require significant investment to go back on offense. ATEC’s sole focus on spine and its procedural approach has resonated with surgeons. To be fair, ATEC has taken market share from all of the market’s major players given its consistent, market-leading growth rate.
VB Spine and Highridge Medical emerged out of large strategics that called it quits on the spine market and both companies have focused on acquiring technology through development or partnership deals to fully compete at the highest echelon of the market.
More specialized players experienced strong year-over-year growth. SI-BONE , Centinel Spine (+34.4%) and Carlsmed (+86%) have parlayed their unique product offerings to substantial growth and could become more disruptive forces as they continue to gain adoption.
Important Developments in the Spine Market
Market Share Moats. In 2023, we talked about how the closed model of robotics and enabling technology was a key initiative for the largest companies to dominate strategically important accounts and protect implant market share. We wondered if the inefficiencies of that model might drive hospital administrators to the open model of robotics. While the open model has taken some steps since then, the closed model appears stronger than ever. Medtronic has benefited from health systems upgrading not just single pieces of capital but adding the full AiBLE ecosystem, which creates a strong competitive moat around the company’s spine business. Still, we expect smaller spine-focused companies to invest in enabling technology to maintain their competitiveness.
Acquisition and Investment Focus. Spine remains the most active category for orthopedic M&A and funding. However, that focus has been shifting to other segments over the last five years. From 2016 to 2020, 30% of all M&A was spine related. From 2021 to 2025, that percentage dropped to 24%. Spine saw a similar drop in funding for those years, going from 30% of all investment announcements to 25%. Looking at dollars invested, the drop is even more precipitous, declining 17%. In both M&A and investments, much of that activity has shifted to digital solutions and orthobiologics.
A Mostly Inpatient Industry. While orthopedic procedures are moving to alternative sites of care, spine surgery is mostly performed at inpatient hospital settings because of procedural complexity, operating requirements and reimbursement dynamics. Inpatient reimbursement has been mostly flat, while outpatient rates have climbed steadily. The remaining gap provides limited financial incentive to move cases to outpatient settings. Some spine surgeries have made meaningful inroads to the ASC, however, including lumbar fusion, simple cervical cases and decompressions.
Motion Preservation Momentum. Non-fusion technologies continue to advance and are expected to gain greater adoption as more implants reach the market and surgeons better qualify the patients best served by these options. Two of three orthopedic Premarket Approvals in 2025 were for spine implants: Companion Spine’s DIAM Spinal Stabilization System and Centinel Spine’s prodiscC Vivo and prodisc C SK Cervical received two-level vertebrae indication. Empirical Spine’s LimiFlex Dynamic Sagittal Tether received a PMA at the beginning of 2026. We expect this portion of the market to grow, as reimbursement improves and surgeons favor minimally invasive procedures for spine candidates.
SI Joint Fusion Remains Hot. The sacroiliac (SI) joint fusion remains one of the faster-growing subsegments of spine due to a greater focus on the segment by surgeons and companies. SI-BONE, a leader in the space, says SI joint dysfunction has a large addressable market with strong fundamentals. While the market is expected to grow due to more minimally invasive options and greater awareness from surgeons, including pain management physicians, we wonder when the segment will reach oversaturation with available products. Established spine companies have added SI joint implants to their portfolios in recent years and three of the seven companies that received their first FDA 510(k) in 2025 introduced an implant in this category.
Saving the Disc. Biologic responses to halt degenerative disc disease is predicted to be the future of spine care. Over two dozen companies are actively developing products for intervertebral disc repair and restoration, establishing a strong pipeline of potential options in the future. These approaches could help bridge the gap between conservative treatment, spinal fusions and disc replacements.
Further Reading
Thanks for visiting! Need more insight on the spine market? Questions and comments are always welcome. You can reach me by email. Until then, I’ve selected a few posts that give insight into our thinking on the spine market.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
